-

Humana Names Dr. Shantanu Nundy as Chief Medical Officer

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced that Shantanu Nundy, M.D., will join the company as Chief Medical Officer, effective August 31. A practicing physician, healthcare executive, and technology leader, Dr. Nundy has spent his career using technology to make care better, simpler, and more human. At Humana, he will bring an innovative clinical voice to the enterprise and help shape the design of the company's products, platforms, and use of AI. Dr. Nundy will report to Jim Rechtin, Humana President and CEO, and will serve as a member of the company’s Enterprise Leadership Team.

“Clinical excellence is at the heart of Humana’s vision to be a leading consumer healthcare company, and I am thrilled to welcome Dr. Nundy as our new chief medical officer,” said Jim Rechtin, Humana President and CEO. “I am confident Shantanu’s experience at the intersection of clinical outcomes, technology, and the consumer experience will advance our efforts to simplify the path to care and help the people we serve achieve their best health.”

Dr. Nundy most recently served as Executive Vice President of Care Delivery and Chief Health Officer at Accolade, a personalized healthcare navigation and care delivery company serving millions of Americans, where he led a technology-driven transformation of the member care experience. Previously, he was Managing Director for Clinical Innovation at Evolent Health, where he drove value-based and digital care transformation across large health systems. He has advised a wide range of organizations on digital health and AI, including the U.S. Food and Drug Administration, World Bank, and a number of health technology startups. Dr. Nundy is a hands-on clinician who practices primary care at a community health center and hospital medicine at a regional health system. He is the author of two books and serves on the adjunct faculty at Stanford Medicine and Johns Hopkins Carey Business School. He earned his bachelor's degree from the Massachusetts Institute of Technology, his medical degree from Johns Hopkins and his MBA from the University of Chicago.

About Humana

Humana is a leading U.S. healthcare company. Through our Humana insurance services, and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.

Contacts

Investors: Lisa Stoner - Humana Investor Relations; (502) 580-2652;
lstamper@humana.com

Media: Mark Taylor - Humana Corporate Communications; (317) 753-0345;
MTaylor108@humana.com

Humana Inc.

NYSE:HUM

Release Versions

Contacts

Investors: Lisa Stoner - Humana Investor Relations; (502) 580-2652;
lstamper@humana.com

Media: Mark Taylor - Humana Corporate Communications; (317) 753-0345;
MTaylor108@humana.com

More News From Humana Inc.

Humana Announces Final Results of Offers to Purchase for Cash Certain of its Outstanding Debt Securities

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) (“Humana”, “we”, or “our”) today announced the expiration and final results of its previously announced cash tender offers (collectively, the “Offers”) to purchase the outstanding 2.150% Senior Notes due February 3, 2032 (the “February 2032 Notes”), 3.125% Senior Notes due August 15, 2029 (the “August 2029 Notes”), 3.700% Senior Notes due March 23, 2029 (the “March 2029 Notes”), 4.875% Senior Notes due April 1, 2030 (the “April 2030 Note...

Humana Announces Pricing Terms of Offers to Purchase for Cash Certain of its Outstanding Debt Securities

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) (“Humana”, “we”, or “our”) today announced the Reference Yield and Total Consideration (as set forth in the table below) to be paid in connection with its previously announced cash tender offers (collectively, the “Offers”) to purchase the outstanding notes described below, in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 9, 2026 (the “Offer to Purchase”). The Notes offered to be...

Humana Commences Offers to Purchase for Cash Certain of its Outstanding Debt Securities

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) (“Humana”, “we”, or “our”) today announced that it has commenced cash tender offers (collectively, the “Offers”) to purchase the outstanding notes described below, in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 9, 2026 (the “Offer to Purchase”). The Notes offered to be purchased in the Offers, in the order of acceptance priority, are the 2.150% Senior Notes due 2032; 3.125% Sen...
Back to Newsroom